Anti-RNA polymerase III antibodies: A marker of systemic sclerosis with rapid onset and skin thickening progression

Ilaria Cavazzana, Ceribelli Angela, Airo' Paolo, Zingarelli Stefania, Tincani Angela, Franceschini Franco

Research output: Contribution to journalArticle

Abstract

Anti-RNA polymerase III antibodies (ARA) are a specific marker for Systemic Sclerosis (SSc), associated to severe disease with major organ and diffuse cutaneous involvement. In our series, ARA were found in 19 of 216 sera, in 15 cases as isolated antibodies' specificity, with a statistically negative association with other SSc-specific autoantibodies (p: 0.00003). The prevalence of ARA among 73 anticentromere and anti-topoisomerase I (topo I) negative sera, was 20.5%. Patients with isolated ARA had more rapid disease onset, defined as the interval from the appearance of Raynaud's phenomenon to the first symptom other than Raynaud's, than patients with isolated anti-topo I antibodies (median: 2 months vs 13 months; p: 0.0013). A rapid onset of SSc (within 6 months from Raynaud's phenomenon onset) was found in all patients with isolated ARA and only in 34% of those with anti-topo I (p <0.00001). Moreover, the skin thickening in the first months after SSc onset was faster in the ARA group (p <0.0001). Nevertheless, the rates of internal organ involvement and of survival rates were similar between the two groups. Our experience therefore suggests that ARA are a marker of very rapid onset of disease and skin thickening progression in SSc.

Original languageEnglish
Pages (from-to)580-584
Number of pages5
JournalAutoimmunity Reviews
Volume8
Issue number7
DOIs
Publication statusPublished - Jun 2009

Fingerprint

RNA Polymerase III
Systemic Scleroderma
Type I DNA Topoisomerase
Skin
Antibodies
Raynaud Disease
Tissue Survival
Antibody Specificity
Serum
Skin Diseases
Autoantibodies
Survival Rate

Keywords

  • Anti-nuclear antibodies
  • Anti-RNA polymerase III
  • Rapid systemic sclerosis onset
  • Raynaud's phenomenon
  • Skin thickening progression
  • Systemic Sclerosis

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Anti-RNA polymerase III antibodies : A marker of systemic sclerosis with rapid onset and skin thickening progression. / Cavazzana, Ilaria; Angela, Ceribelli; Paolo, Airo'; Stefania, Zingarelli; Angela, Tincani; Franco, Franceschini.

In: Autoimmunity Reviews, Vol. 8, No. 7, 06.2009, p. 580-584.

Research output: Contribution to journalArticle

Cavazzana, Ilaria ; Angela, Ceribelli ; Paolo, Airo' ; Stefania, Zingarelli ; Angela, Tincani ; Franco, Franceschini. / Anti-RNA polymerase III antibodies : A marker of systemic sclerosis with rapid onset and skin thickening progression. In: Autoimmunity Reviews. 2009 ; Vol. 8, No. 7. pp. 580-584.
@article{54a2563944b44bcfb6b1fffca324d52a,
title = "Anti-RNA polymerase III antibodies: A marker of systemic sclerosis with rapid onset and skin thickening progression",
abstract = "Anti-RNA polymerase III antibodies (ARA) are a specific marker for Systemic Sclerosis (SSc), associated to severe disease with major organ and diffuse cutaneous involvement. In our series, ARA were found in 19 of 216 sera, in 15 cases as isolated antibodies' specificity, with a statistically negative association with other SSc-specific autoantibodies (p: 0.00003). The prevalence of ARA among 73 anticentromere and anti-topoisomerase I (topo I) negative sera, was 20.5{\%}. Patients with isolated ARA had more rapid disease onset, defined as the interval from the appearance of Raynaud's phenomenon to the first symptom other than Raynaud's, than patients with isolated anti-topo I antibodies (median: 2 months vs 13 months; p: 0.0013). A rapid onset of SSc (within 6 months from Raynaud's phenomenon onset) was found in all patients with isolated ARA and only in 34{\%} of those with anti-topo I (p <0.00001). Moreover, the skin thickening in the first months after SSc onset was faster in the ARA group (p <0.0001). Nevertheless, the rates of internal organ involvement and of survival rates were similar between the two groups. Our experience therefore suggests that ARA are a marker of very rapid onset of disease and skin thickening progression in SSc.",
keywords = "Anti-nuclear antibodies, Anti-RNA polymerase III, Rapid systemic sclerosis onset, Raynaud's phenomenon, Skin thickening progression, Systemic Sclerosis",
author = "Ilaria Cavazzana and Ceribelli Angela and Airo' Paolo and Zingarelli Stefania and Tincani Angela and Franceschini Franco",
year = "2009",
month = "6",
doi = "10.1016/j.autrev.2009.02.002",
language = "English",
volume = "8",
pages = "580--584",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier",
number = "7",

}

TY - JOUR

T1 - Anti-RNA polymerase III antibodies

T2 - A marker of systemic sclerosis with rapid onset and skin thickening progression

AU - Cavazzana, Ilaria

AU - Angela, Ceribelli

AU - Paolo, Airo'

AU - Stefania, Zingarelli

AU - Angela, Tincani

AU - Franco, Franceschini

PY - 2009/6

Y1 - 2009/6

N2 - Anti-RNA polymerase III antibodies (ARA) are a specific marker for Systemic Sclerosis (SSc), associated to severe disease with major organ and diffuse cutaneous involvement. In our series, ARA were found in 19 of 216 sera, in 15 cases as isolated antibodies' specificity, with a statistically negative association with other SSc-specific autoantibodies (p: 0.00003). The prevalence of ARA among 73 anticentromere and anti-topoisomerase I (topo I) negative sera, was 20.5%. Patients with isolated ARA had more rapid disease onset, defined as the interval from the appearance of Raynaud's phenomenon to the first symptom other than Raynaud's, than patients with isolated anti-topo I antibodies (median: 2 months vs 13 months; p: 0.0013). A rapid onset of SSc (within 6 months from Raynaud's phenomenon onset) was found in all patients with isolated ARA and only in 34% of those with anti-topo I (p <0.00001). Moreover, the skin thickening in the first months after SSc onset was faster in the ARA group (p <0.0001). Nevertheless, the rates of internal organ involvement and of survival rates were similar between the two groups. Our experience therefore suggests that ARA are a marker of very rapid onset of disease and skin thickening progression in SSc.

AB - Anti-RNA polymerase III antibodies (ARA) are a specific marker for Systemic Sclerosis (SSc), associated to severe disease with major organ and diffuse cutaneous involvement. In our series, ARA were found in 19 of 216 sera, in 15 cases as isolated antibodies' specificity, with a statistically negative association with other SSc-specific autoantibodies (p: 0.00003). The prevalence of ARA among 73 anticentromere and anti-topoisomerase I (topo I) negative sera, was 20.5%. Patients with isolated ARA had more rapid disease onset, defined as the interval from the appearance of Raynaud's phenomenon to the first symptom other than Raynaud's, than patients with isolated anti-topo I antibodies (median: 2 months vs 13 months; p: 0.0013). A rapid onset of SSc (within 6 months from Raynaud's phenomenon onset) was found in all patients with isolated ARA and only in 34% of those with anti-topo I (p <0.00001). Moreover, the skin thickening in the first months after SSc onset was faster in the ARA group (p <0.0001). Nevertheless, the rates of internal organ involvement and of survival rates were similar between the two groups. Our experience therefore suggests that ARA are a marker of very rapid onset of disease and skin thickening progression in SSc.

KW - Anti-nuclear antibodies

KW - Anti-RNA polymerase III

KW - Rapid systemic sclerosis onset

KW - Raynaud's phenomenon

KW - Skin thickening progression

KW - Systemic Sclerosis

UR - http://www.scopus.com/inward/record.url?scp=67349243081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349243081&partnerID=8YFLogxK

U2 - 10.1016/j.autrev.2009.02.002

DO - 10.1016/j.autrev.2009.02.002

M3 - Article

C2 - 19393210

AN - SCOPUS:67349243081

VL - 8

SP - 580

EP - 584

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

SN - 1568-9972

IS - 7

ER -